Tweets by IDWeek 2023

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

267 Views

054. HAI: C. difficile: Thursday, 12:15 - 1:30 p.m.

Poster Session: HAI: C. difficile

(702) Efficacy of Fecal Microbiota, Live-jslm After Receipt of Non–Clostridioides difficile Infection Antibiotics: Post Hoc Subgroup Analysis of a Phase 2 Open-Label Trial

Thursday, October 12, 2023

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Co-Author(s)

Kelly R. Reveles, PharmD, PhD

Associate Professor
The University of Texas at Austin
San Antonio, Texas, United States

Anne J. Gonzales-Luna, PharmD, BCIDP (she/her/hers)

Assistant Professor
Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy
Houston, TX, United States
YG

Yoav Golan, MD

Tufts Medical Center
Boston, Massachusetts, United States
CA

Carolyn D. Alonso, MD

Principal Investigator
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
BG

Beth Guthmueller, AS

Rebiotix Inc., a Ferring Company
Roseville, Minnesota, United States
XT

Xing Tan, PharmD

Ferring Pharmaceuticals
Parsippany, New Jersey, United States
MB

Monique Bidell, PharmD

Ferring Pharmaceuticals
Parsippany, New Jersey, United States
VP

Victoria Pokhilko, PhD

Ferring Pharmaceuticals
Parsippany, New Jersey, United States
CC

Carl Crawford, MD

Weill Cornell Medicine
New York, New York, United States

Andrew M. Skinner, MD

Assistant Professor
University of Utah
Salt Lake City, UT, United States